Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of V70P5 Revaccination Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 13.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female children that have previously participated in the V70P5 study in Finland.~Exclusion Criteria:~* Any condition which in the opinion of the investigator may interfere with the evaluation of the study objectives.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 96 Months
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): None
- Group 2 (Type: EXPERIMENTAL): None
- Group 3 (Type: EXPERIMENTAL): None
- Group 4 (Type: EXPERIMENTAL): None
- Group 5 (Type: EXPERIMENTAL): None
- Group 6 (Type: EXPERIMENTAL): None
- Group 7 (Type: EXPERIMENTAL): None
- Group 8 (Type: EXPERIMENTAL): None
- Group 9 (Type: EXPERIMENTAL): None
- Group 10 (Type: EXPERIMENTAL): None
- Group 11 (Type: EXPERIMENTAL): None
- Group 12 (Type: EXPERIMENTAL): None
- Group 13 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).